NI201100099A - Nuevos compuestos 578. - Google Patents

Nuevos compuestos 578.

Info

Publication number
NI201100099A
NI201100099A NI201100099A NI201100099A NI201100099A NI 201100099 A NI201100099 A NI 201100099A NI 201100099 A NI201100099 A NI 201100099A NI 201100099 A NI201100099 A NI 201100099A NI 201100099 A NI201100099 A NI 201100099A
Authority
NI
Nicaragua
Prior art keywords
dementia
disease
alzheimer
cognitive impairment
limited
Prior art date
Application number
NI201100099A
Other languages
English (en)
Inventor
Holenz Jörg
Von Berg Stefan
Karlström Sofia
Kolmodin Karin
Lindström Johan
Rakos Laszlo
Rotticci Didier
Söderman Peter
Swahn Britt-Marie
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42170158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201100099(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NI201100099A publication Critical patent/NI201100099A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de fórmula (I) y su composiciones farmacéuticas. Adicionalmente, la presente invención se refiere a métodos terapéuticos para el tratamiento y/o prevención de patologías relacionadas con Abeta tales como síndrome de Down, angiopatía 13-amiloide tal como, a modo no taxativo, angiopatía amiloide cerebral o hemorragia cerebral hereditaria, trastornos asociados con deficiencia cognitiva tales como, a modo no taxativo, deterioro cognitivo leve, enfermedad de Alzheimer, pérdida de memoria, síntomas de déficit atencional asociados con la enfermedad de Alzheimer, neurodegeneración asociada con enfermedades tales como enfermedad de Alzheimer o demencia, incluyendo demencia de origen mixto vascular y degenerativo, demencia presenil, demencia senil y demencia asociada con la enfermedad de Parkinson, parálisis supranuclear progresiva o degeneración córtico-basal.
NI201100099A 2008-11-14 2011-05-13 Nuevos compuestos 578. NI201100099A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11463408P 2008-11-14 2008-11-14
US13976708P 2008-12-22 2008-12-22
US22165309P 2009-06-30 2009-06-30

Publications (1)

Publication Number Publication Date
NI201100099A true NI201100099A (es) 2012-03-19

Family

ID=42170158

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201100099A NI201100099A (es) 2008-11-14 2011-05-13 Nuevos compuestos 578.

Country Status (24)

Country Link
US (2) US8030500B2 (es)
EP (1) EP2367814A4 (es)
JP (1) JP2012508734A (es)
KR (1) KR20110091540A (es)
CN (1) CN102282140A (es)
AR (1) AR074341A1 (es)
AU (1) AU2009314664A1 (es)
BR (1) BRPI0921879A2 (es)
CA (1) CA2743938A1 (es)
CL (1) CL2011001098A1 (es)
CO (1) CO6362004A2 (es)
CR (1) CR20110255A (es)
CU (1) CU20110106A7 (es)
DO (1) DOP2011000138A (es)
EA (1) EA201190020A1 (es)
EC (1) ECSP11011051A (es)
IL (1) IL212590A0 (es)
MX (1) MX2011004918A (es)
NI (1) NI201100099A (es)
PE (1) PE20110875A1 (es)
TW (1) TW201020244A (es)
UY (1) UY32241A (es)
WO (1) WO2010056196A1 (es)
ZA (1) ZA201104396B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006307314C1 (en) 2005-10-25 2011-08-25 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
TW200815349A (en) * 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
TW200902526A (en) 2007-04-24 2009-01-16 Shionogi & Amp Co Ltd Aminodihydrothiazin derivative substituted with a cyclic group
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
WO2009151098A1 (ja) 2008-06-13 2009-12-17 塩野義製薬株式会社 βセクレターゼ阻害作用を有する含硫黄複素環誘導体
WO2010047372A1 (ja) 2008-10-22 2010-04-29 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
TW201144295A (en) * 2010-05-12 2011-12-16 Astrazeneca Ab Hemifumarate salt
EP2601197B1 (en) 2010-08-05 2014-06-25 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
US20120165346A1 (en) * 2010-12-22 2012-06-28 Astrazeneca Ab Compounds and their use as BACE inhibitors
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
US10707526B2 (en) 2015-03-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
CN105272884B (zh) * 2015-11-02 2017-05-24 浙江大学 一种邻氰基二苯甲酮衍生物的制备方法
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) * 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
DK0730643T3 (da) * 1993-10-27 2001-05-14 Elan Pharm Inc Transgene dyr, som huser APP-allel med svensk mutation
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
DE4419849A1 (de) 1994-06-07 1995-12-14 Hoechst Ag Isoindolinpigmente
CZ287613B6 (en) 1994-06-16 2001-01-17 Pfizer Pyrazolo- and pyrrolopyridines and pharmaceutical preparations based thereon
DE19516804A1 (de) * 1995-05-08 1996-11-14 Hoechst Ag Isoindolinpigmente auf Basis von Aminochinoxalindionen
JPH11507538A (ja) * 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US6211235B1 (en) * 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
AU9041198A (en) 1997-09-02 1999-03-22 Du Pont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
US5981168A (en) * 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
CN1502692A (zh) 1998-09-24 2004-06-09 �������Ŷ���Լ��������˾ 阿尔茨海默氏疾病分泌酶
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
AU4000900A (en) 1999-02-10 2000-08-29 Elan Pharmaceuticals, Inc. Beta-secretase enzyme compositions and methods
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
AU5619400A (en) 1999-06-15 2001-01-02 Elan Pharmaceuticals, Inc. Statine-derived tetrapeptide inhibitors of beta-secretase
EP1194449B1 (en) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
EP1224297B1 (en) 1999-09-23 2009-05-13 Pharmacia & Upjohn Company LLC Alzheimer's disease secretase, app substrates therefor, and uses therefor
GB9924957D0 (en) 1999-10-21 1999-12-22 Smithkline Beecham Plc Novel treatment
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
CA2410680A1 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2002014264A2 (en) 2000-08-11 2002-02-21 The Brigham And Women's Hospital, Inc. (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production
AU2001292843A1 (en) 2000-09-22 2002-04-02 Wyeth Crystal structure of bace and uses thereof
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
MY148233A (en) 2003-12-15 2013-03-29 Merck Sharp & Dohme Heterocyclic aspartyl protease inhibitors
WO2005097767A1 (en) 2004-03-30 2005-10-20 Merck & Co., Inc. 2-aminothiazole compounds useful as aspartyl protease inhibitors
US20080153869A1 (en) 2004-06-14 2008-06-26 Bressi Jerome C Kinase Inhibitors
AU2005264917A1 (en) 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase
ES2332659T3 (es) * 2004-06-16 2010-02-10 Wyeth Derivados de amino-5,5-difenilimidazolona para la inhibicion de beta-secretasa.
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006034419A2 (en) 2004-09-21 2006-03-30 Athersys, Inc. Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof
US20090062282A1 (en) 2004-10-15 2009-03-05 Astrazeneca Ab Substituted Amino-Pyrimidones and Uses Thereof
WO2006041404A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-compounds and uses thereof
JP2008523139A (ja) 2004-12-14 2008-07-03 アストラゼネカ・アクチエボラーグ 置換アミノピリジン類及びその使用
EP2264036A1 (en) * 2005-01-14 2010-12-22 Wyeth LLC (Formerly Known As Wyeth) Amino-imidazolones for the inhibition of beta-secretase
EP1863771B1 (en) 2005-03-14 2012-11-07 High Point Pharmaceuticals, LLC Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors
CN101193892A (zh) * 2005-06-14 2008-06-04 先灵公司 大环杂环天冬氨酰基蛋白酶抑制剂
TW201004961A (en) 2005-06-14 2010-02-01 Schering Corp Aspartyl protease inhibitors
KR20080025079A (ko) * 2005-06-14 2008-03-19 쉐링 코포레이션 아스파르틸 프로테아제 억제제
AR054618A1 (es) 2005-06-14 2007-07-04 Schering Corp Compuestos de azetidina y su uso como inhibidores de proteasas
US8110682B2 (en) 2005-06-14 2012-02-07 Schering Corporation Preparation and use of compounds as aspartyl protease inhibitors
ES2436795T3 (es) 2005-06-14 2014-01-07 Merck Sharp & Dohme Corp. Inhibidores heterocíclicos de aspartil proteasa, preparación y uso de los mismos
MX2008000212A (es) * 2005-06-30 2008-03-24 Wyeth Corp Compuestos amino-5-(6 miembros)heteroarilimidazolona y el uso de estos para la modulacion de la (-secretasa.
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
EP1910364B1 (en) 2005-07-18 2012-03-21 Merck Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
US7601751B2 (en) * 2005-09-01 2009-10-13 Bristol-Myers Squibb Company Indole acetic acid acyl guanidines as β-secretase inhibitors
AU2006307314C1 (en) * 2005-10-25 2011-08-25 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
ATE478070T1 (de) * 2005-10-27 2010-09-15 Schering Corp Heterozyklische aspartyl-proteasehemmer
CA2628264A1 (en) * 2005-10-31 2007-05-10 Schering Corporation Aspartyl protease inhibitors
US20080318985A1 (en) 2005-11-15 2008-12-25 Astrazeneca Ab Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use
JP2009515949A (ja) 2005-11-15 2009-04-16 アストラゼネカ・アクチエボラーグ 新規な２−アミノピリミジノン誘導体およびそれらの使用
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
EP1951681A4 (en) 2005-11-15 2011-06-15 Astrazeneca Ab NEW 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR USE
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
CN101360716A (zh) 2005-11-21 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途
AR058381A1 (es) 2005-12-19 2008-01-30 Astrazeneca Ab Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica
JP2009532464A (ja) 2006-04-05 2009-09-10 アストラゼネカ・アクチエボラーグ ２−アミノピリミジン−４−オン及びＡβ−関連の病理を治療又は予防するためのその使用
TW200808751A (en) 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
CA2653650A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
WO2008063114A1 (en) 2006-11-20 2008-05-29 Astrazeneca Ab Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
WO2008076044A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
TW200902499A (en) * 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
TW200902503A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
WO2009005471A1 (en) * 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2009005470A1 (en) 2007-07-05 2009-01-08 Astrazeneca Ab Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
US20100125081A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 574
US20100125087A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use

Also Published As

Publication number Publication date
UY32241A (es) 2010-06-30
CN102282140A (zh) 2011-12-14
BRPI0921879A2 (pt) 2018-10-16
EP2367814A1 (en) 2011-09-28
CR20110255A (es) 2011-07-04
CU20110106A7 (es) 2012-01-31
US20100125082A1 (en) 2010-05-20
US20110319426A1 (en) 2011-12-29
TW201020244A (en) 2010-06-01
ZA201104396B (en) 2012-03-28
US8030500B2 (en) 2011-10-04
MX2011004918A (es) 2011-05-30
CO6362004A2 (es) 2012-01-20
AU2009314664A1 (en) 2011-06-23
EP2367814A4 (en) 2012-07-04
EA201190020A1 (ru) 2012-02-28
CA2743938A1 (en) 2010-05-20
DOP2011000138A (es) 2011-06-30
WO2010056196A1 (en) 2010-05-20
JP2012508734A (ja) 2012-04-12
ECSP11011051A (es) 2011-06-30
PE20110875A1 (es) 2012-01-11
AR074341A1 (es) 2011-01-12
IL212590A0 (en) 2011-07-31
CL2011001098A1 (es) 2012-02-24
KR20110091540A (ko) 2011-08-11

Similar Documents

Publication Publication Date Title
NI201100099A (es) Nuevos compuestos 578.
NI201300055A (es) Compuestos y su uso como inhibidores de bace
WO2008152099A3 (en) Aryl/hetarylamides as modulators of the ep2 receptor
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
MX2010008700A (es) Moduladores de beta-amiloide.
DOP2012000067A (es) Compuestos de dióxido de iminotiadiazina como inhibidores de enzima de disociacion de app de sitio beta ( bace), composiciones, y su uso
BRPI0909040B8 (pt) derivados de azetidina e ciclobutano, seus usos, e composição
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
WO2009069032A3 (en) Novel glucocorticoid receptor agonists
WO2008152093A3 (en) Diaminopyrimidines as modulators of the ep2 receptor
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
UY32750A (es) Imidazoles sustituidos y uso de los mismos
MX2007010400A (es) Nuevas sales de derivados de hexahidrofenantridina sustituida con 6-heterociclilo.
CO6362008A2 (es) Compuestos n- sulfonamido pirazolil policiclicos
AR081389A1 (es) Sal de tipo hemifumarato, composicion farmaceutica y proceso de obtencion de la misma.
WO2009109501A3 (en) Ocular pharmaceutical compositions
GT200600425A (es) Compuestos de imidazol para el tratamiento de trastornos neurologicos
UY36347A (es) Compuestos y su uso como inhibidores de bace
WO2008152094A3 (en) Substituted acetamides as modulators of the ep2 receptor
CU20130083A7 (es) Compuestos y su uso como inhibidores de bace
WO2011015646A3 (en) Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
CL2012001479A1 (es) Compuestos derivados de azabiciclo[3.1.0]hex-2-ilo, inhibidores de acetilcolinesterasa; compuestos intermediarios; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, tal como narcolepsia, hipersomnias, somnolencias diurnas.
UA109918C2 (xx) Спіропохідні аміноімідазолів та їх застосування як bace-інгібіторів
TH112188A (th) ไอโซอินโดลที่ถูกแทนที่ในฐานะตัวยับยั้ง bace และการใช้
TH155329A (th) สารประกอบและการใช้สารเหล่านี้เป็นตัวยับยั้ง bace